Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D

Abstract

Calcitriol, the hormonally active form of vitamin D, is being evaluated in clinical trials as an anti-cancer agent.

Calcitriol exerts multiple anti-proliferative, pro-apoptotic, and pro-differentiating actions on various malignant cells and retards tumor growth in animal models of cancer.

Calcitriol also exhibits several anti-inflammatory effects including suppression of prostaglandin (PG) action, inhibition of p38 stress kinase signaling, and the subsequent production of pro-inflammatory cytokines and inhibition of NF-κB signaling.

Calcitriol also decreases the expression of aromatase, the enzyme that catalyzes estrogen synthesis in breast cancer, both by a direct transcriptional repression and indirectly by reducing PGs, which are major stimulators of aromatase transcription.

Other important effects include the suppression of tumor angiogenesis, invasion, and metastasis.

These calcitriol actions provide a basis for its potential use in cancer therapy and chemoprevention.

We summarize the status of trials involving calcitriol and its analogs, used alone or in combination with known anti-cancer agents.

About this publication.

See also:

- Vitamin D (analogues and/or derivatives) and cancer;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;